2-Hydroxypropyl-β-cyclodextrin-Hydroxypropyl-betadex-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemE(2-Hydroxypropyl)-β-cyclodextrinCat.No.:HY-101103CASNo.:128446-35-5Synonyms:Hydroxypropylbetadex;Hydroxypropyl-β-cyclodextrin;HP-β-CD作?靶點:Others作?通路:Others儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:50mg/mL(Needultrasonic)H2O:50mg/mL(Needultrasonic)請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(InfinitymM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(InfinitymM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(InfinitymM);Clearsolution4.請依序添加每種溶劑：PBSSolubility:100mg/mL(InfinitymM);Clearsolution;Needultrasonicandwarmingandheatto60°C5.請依序添加每種溶劑：SalineSolubility:200mg/mL(InfinitymM);Clearsolution;Needultrasonic1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性(2-Hydroxypropyl)-β-cyclodextrin?泛使?的藥物遞送載體，可提?穩(wěn)定性和利?度。體外研究Celltreatmentwith(2-Hydroxypropyl)-β-cyclodextrinresultsintheactivationofthetranscriptionfactorEB,amasterregulatoroflysosomalfunctionandautophagy,andinenhancementofthecellularautophagicclearancecapacity[1].(2-Hydroxypropyl)-β-cyclodextrintreatmentreducesintracellularcholesterolresultinginsignificantleukemiccellgrowthinhibitionthroughG2/Mcell-cyclearrestandapoptosis.TheIC50valuesfor(2-Hydroxypropyl)-β-cyclodextrinafter72hoursexposureareintherangeof3.86–10.09mM.(2-Hydroxypropyl)-β-cyclodextrinalsoshowsanticancereffectsagainstCMLcellsexpressingaT315IBCR-ABLmutation(thatconfersresistancetomostABLtyrosinekinaseinhibitors),andhypoxia-adaptedCMLcellsthathavecharacteristicsofleukemicstemcells.Inaddition,colonyformingabilityofhumanprimaryAMLandCMLcellsisinhibitedby(2-Hydroxypropyl)-β-cyclodextrin[2].體內(nèi)研究(2-Hydroxypropyl)-β-cyclodextrinadministrationpromotestranscriptionfactorEB-mediatedclearanceofproteolipidaggregatesthataccumulateduetoinefficientactivityofthelysosome-autophagysystemincellsderivedfromapatientwithalysosomalstoragedisorder[1].Intraperitonealinjectionof(2-Hydroxypropyl)-β-cyclodextrinsignificantlyimprovessurvivalinleukemiamousemodels.Systemicadministrationof(2-Hydroxypropyl)-β-cyclodextrintomicehasnosignificantadverseeffects[2].PROTOCOLCellAssay[2]Cellsareincubatedwith(2-Hydroxypropyl)-β-cyclodextrinatvariousconcentrations(5,7.5,10,15,20mM)for72hours.Cellviabilityisassessedusingatrypanbluedyeexclusionmethodandcellproliferationisevaluatedusingamodifiedmethyl-thiazol-diphenyl-tetrazolium(MTT)assay[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.AnimalMice:Miceareintraperitoneallyinjectedwith200μLvehicle(saline)or(2-Hydroxypropyl)-β-cyclodextrin(50Administration[2]or150mM)for20consecutivedays3daysaftertransplantation,andsurvivalismonitoreddaily.LeukemiccellengraftmentisconfirmedbydetectionofGFP-positivecellsintherecipient’sBMusingflowcytometry[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻?NatCommun.2022May31;13(1):3022.?CellRep.2018Dec11;25(11):2972-2980.e5.?CancerCellInt.2021Apr15;21(1):216.?FrontCellInfectMicrobiol.2021Jul23;11:705087.?IntImmunopharmacol.2021Apr17;96:107643.Seemorecustomervalidationsonwww.MedChemEREFERENCES2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[1].SongW,etal.2-Hydroxypropyl-β-cyclodextrinpromotestranscriptionfactorEB-mediatedactivationofautophagy:implicationsfortherapy.JBiolChem.2014Apr4;289(14):10211-22.[2].YokooM,etal.2-Hydroxypropyl-β-CyclodextrinActsasaNovelAnticancerAgent.PLoSOne.2015Nov4;10(11):e01